C14orf180 | Chromosome 14 open reading frame 180 | Predicted membrane proteins
| | | | | Group enriched |
DIRAS1 | DIRAS family, GTP-binding RAS-like 1 | | | | | | Group enriched |
GABRB1 | Gamma-aminobutyric acid (GABA) A receptor, beta 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GRM1 | Glutamate receptor, metabotropic 1 | Disease related genes G-protein coupled receptors Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
HCN2 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNIP2 | Kv channel interacting protein 2 | | | | | | Group enriched |
KCNJ4 | Potassium inwardly-rectifying channel, subfamily J, member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
LPL | Lipoprotein lipase | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
SCN2B | Sodium channel, voltage-gated, type II, beta subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
SPHKAP | SPHK1 interactor, AKAP domain containing | | | | | | Group enriched |
SYNPR | Synaptoporin | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ABRA | Actin-binding Rho activating protein | | | | | | Group enriched |
ACTN2 | Actinin, alpha 2 | Cytoskeleton related proteins Disease related genes Plasma proteins
| | | | | Group enriched |
ADPRHL1 | ADP-ribosylhydrolase like 1 | | | | | | Group enriched |
ALPK3 | Alpha-kinase 3 | Enzymes
| | | | | Group enriched |
ANKRD2 | Ankyrin repeat domain 2 (stretch responsive muscle) | | | | | | Group enriched |
APOBEC2 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 | | | | | | Group enriched |
ART3 | ADP-ribosyltransferase 3 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ASB11 | Ankyrin repeat and SOCS box containing 11 | Predicted membrane proteins
| | | | | Group enriched |
ASB15 | Ankyrin repeat and SOCS box containing 15 | | | | | | Group enriched |
ASB18 | Ankyrin repeat and SOCS box containing 18 | Predicted membrane proteins
| | | | | Group enriched |
ATP1A3 | ATPase, Na+/K+ transporting, alpha 3 polypeptide | Disease related genes Enzymes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
C10orf71 | Chromosome 10 open reading frame 71 | | | | | | Group enriched |
C20orf26 | Chromosome 20 open reading frame 26 | Predicted membrane proteins
| | | | | Group enriched |
CAMK2B | Calcium/calmodulin-dependent protein kinase II beta | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
CAND2 | Cullin-associated and neddylation-dissociated 2 (putative) | | | | | | Group enriched |
CAV3 | Caveolin 3 | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CKMT2 | Creatine kinase, mitochondrial 2 (sarcomeric) | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Group enriched |
CMYA5 | Cardiomyopathy associated 5 | | | | | | Group enriched |
COQ10A | Coenzyme Q10 homolog A (S. cerevisiae) | Mitochondrial proteins
| | | | | Group enriched |
CORO6 | Coronin 6 | | | | | | Group enriched |
COX6A2 | Cytochrome c oxidase subunit VIa polypeptide 2 | Mitochondrial proteins Transporters
| | | | | Group enriched |
COX7A1 | Cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) | Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
CSRP3 | Cysteine and glycine-rich protein 3 (cardiac LIM protein) | Cytoskeleton related proteins Disease related genes Plasma proteins
| | | | | Group enriched |
DCUN1D2 | DCN1, defective in cullin neddylation 1, domain containing 2 | | | | | | Group enriched |
DHRS7C | Dehydrogenase/reductase (SDR family) member 7C | Predicted secreted proteins
| | | | | Group enriched |
DNAAF3 | Dynein, axonemal, assembly factor 3 | Disease related genes
| | | | | Group enriched |
DUSP27 | Dual specificity phosphatase 27 (putative) | | | | | | Group enriched |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
FABP3 | Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) | Candidate cardiovascular disease genes Plasma proteins
| | | | | Group enriched |
FAM155B | Family with sequence similarity 155, member B | Predicted membrane proteins
| | | | | Group enriched |
FAM69C | Family with sequence similarity 69, member C | | | | | | Group enriched |
FBXO40 | F-box protein 40 | Plasma proteins
| | | | | Group enriched |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets RAS pathway related proteins
| | | | | Group enriched |
FHL2 | Four and a half LIM domains 2 | | | | | | Group enriched |
FITM1 | Fat storage-inducing transmembrane protein 1 | Predicted membrane proteins
| | | | | Group enriched |
FRMD5 | FERM domain containing 5 | Cytoskeleton related proteins Predicted membrane proteins
| | | | | Group enriched |
FSD2 | Fibronectin type III and SPRY domain containing 2 | | | | | | Group enriched |
GABRA4 | Gamma-aminobutyric acid (GABA) A receptor, alpha 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |